Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.

BACKGROUND Atrophy is recognized as a measure of destructive changes in multiple sclerosis (MS). The time course and pathologic mechanisms of atrophy development are not well understood. Significant atrophy was reported to occur within 9 to 12 months in relapsing remitting MS. OBJECTIVES To test whether atrophy can be detected over short time intervals, and to evaluate its relationship to inflammation. DESIGN AND METHODS Prior to randomization to a treatment trial, 138 untreated patients with relapsing remitting MS had 3 magnetic resonance imaging scans within a mean +/- SD follow-up of 76 +/- 20.2 days. Brain parenchymal fraction (BPF), a normalized measure of whole brain volume, the proportion of active (gadolinium-enhancing) scans, and the volume of T1-weighted gadolinium-enhancing and T2-weighted hyperintense lesions were determined at all time points. An annualized atrophy rate was estimated by calculating a regression slope. RESULTS The median Expanded Disability Status Scale score was 3.5, the mean disease duration was 7.6, and the mean age was 38.5 years. The BPF decreased significantly by -0.229% from scan 1 to scan 3, while the proportion of active scans remained high (65%, 63%, and 67%). The BPF change was only weakly correlated to the volume of T1-weighted gadolinium-enhancing lesions in scan 1 (r = -0.185). The estimated annualized atrophy rate was -1.06% (95% confidence interval, -1.50% to -0.62%). CONCLUSIONS The annualized atrophy rate found in this study is comparable with rates reported previously. Measurements of BPF allow detection of atrophy over short time intervals in active disease. The short-term relationship of inflammation to atrophy development was weak. Brain parenchymal fraction might be a promising measure in future phase 2 studies of agents, with an expected effect on tissue-destructive pathologic mechanisms of MS.

[1]  M Niewald,et al.  Significant reversibility of alcoholic brain shrinkage within 3 weeks of abstinence , 1995, Acta psychiatrica Scandinavica.

[2]  L D Blumhardt,et al.  Short‐term ventricular volume changes on serial MRI in multiple sclerosis , 2000, Acta neurologica Scandinavica.

[3]  B. Lewis,et al.  Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b , 2002, Neurology.

[4]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[5]  Nick C Fox,et al.  Haemodialysis and Cerebral Oedema , 2001, Nephron.

[6]  J. Udupa,et al.  The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS , 2000, Neurology.

[7]  J. Simon.  From enhancing lesions to brain atrophy in relapsing MS , 1999, Journal of Neuroimmunology.

[8]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[9]  C. Pozzilli,et al.  MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a , 2002, Multiple sclerosis.

[10]  S J Nelson,et al.  A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis , 2000, Multiple sclerosis.

[11]  M N Rossor,et al.  Progressive cerebral atrophy in MS , 2000, Neurology.

[12]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[13]  H. Adams,et al.  Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.

[14]  M Rovaris,et al.  Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. , 2001, Brain : a journal of neurology.